Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 2, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 6, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001681643-26-000002
Filed / recorded
Jan 6, 2026, 9:21 PM UTC
Added to OQRO
Oct 2, 2026, 12:28 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
REGENERON PHARMACEUTICALS, INC.
Issuer CIK
872589
Ticker
REGN
Reporting person
Huda Y Zoghbi
Relationship
Director
Security
Non-Qualified Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Jan 2, 2026
Transaction code
A
Shares / units
1,962
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
1,962
Ownership form
Direct
Amendment
No
Footnotes from the filing
On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.